Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda
- R. L. Goodall
- D. T. Dunn
- T. Pattery
- A. van Cauwenberge
- P. Nkurunziza
- P. Awio
- N. Ndembi
- P. Munderi
- C. Kityo
- C. F. Gilks
- P. Kaleebu
- D. Pillay
- P. Kaleebu
- D. Pillay
- P. Awio
- M. Chirara
- D. Dunn
- D. M. Gibb
- C. Gilks
- R. Goodall
- A. Kapaata
- M. Katuramur
- F. Lyagoba
- R. Magala
- B. Magambo
- K. Mataruka
- A.L. McCormick
- L. Mugarura
- T. Musunga
- M. Nabankkema
- J. Nkalubo
- P. Nkurunziza
- C. Parry
- V. Robertson
- M. Spyer
- D. Yirrell
- H. Grosskurth
- P. Munderi
- G. Kabuye
- D. Nsibambi
- R. Kasirye
- E. Zalwango
- M. Nakazibwe
- B. Kikaire
- G. Nassuna
- R. Massa
- K. Fadhiru
- M. Namyalo
- A. Zalwango
- L. Generous
- P. Khauka
- R. L. Goodall
- D. T. Dunn
- T. Pattery
- A. van Cauwenberge
- P. Nkurunziza
- P. Awio
- N. Ndembi
- P. Munderi
- C. Kityo
- C. F. Gilks
- P. Kaleebu
- D. Pillay
- P. Kaleebu
- D. Pillay
- P. Awio
- M. Chirara
- D. Dunn
- D. M. Gibb
- C. Gilks
- R. Goodall
- A. Kapaata
- M. Katuramur
- F. Lyagoba
- R. Magala
- B. Magambo
- K. Mataruka
- A.L. McCormick
- L. Mugarura
- T. Musunga
- M. Nabankkema
- J. Nkalubo
- P. Nkurunziza
- C. Parry
- V. Robertson
- M. Spyer
- D. Yirrell
- H. Grosskurth
- P. Munderi
- G. Kabuye
- D. Nsibambi
- R. Kasirye
- E. Zalwango
- M. Nakazibwe
- B. Kikaire
- G. Nassuna
- R. Massa
- K. Fadhiru
- M. Namyalo
- A. Zalwango
- L. Generous
- P. Khauka
DOIAbstract
Objectives We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological monitoring. Methods NORA [Nevirapine OR Abacavir study, a sub-study of the Development of AntiRetroviral Therapy in Africa (DART) trial] randomized 600 symptomatic HIV-infected Ugandan adults (CD4 cell count <200 cells/mm3) to receive zidovudine/lamivudine plus abacavir (cABC arm) or nevirapine (cNVP arm). All virological tests were performed retrospectively, including resistance tests on week 96 plasma samples with HIV RNA levels ≥1000 copies/mL. Phenotypic resistance was expressed as fold-change in IC50 (FC) relative to wild-type virus. Results HIV-1 RNA viral load ≥1000 copies/...
Add to ORKG